DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Miltefosine
Miltefosine
Miltefosine Combined with Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia
204684Orig1s000
Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania Infantum, Causing Alterations in Redox Balance And
Treatment of Visceral Leishmaniasis with Intravenous Pentamidine And
Lopinavir, an HIV-1 Peptidase Inhibitor, Induces Alteration on the Lipid Metabolism of Cambridge.Org/Par Leishmania Amazonensis Promastigotes
Interactions with Protease Inhibitors Charts Revised February 2018
Clinical Trial Protocol
World Health Organization Model List of Essential Medicines, 21St List, 2019
204684Orig1s000
In Silico and in Vitro Comparative Activity of Green Tea Components Against Leishmania Infantum
Environmentally Classified Pharmaceuticals 2014-2015
WHO Drug Information Vol
Single Oral Fixed-Dose Praziquantel-Miltefosine
In Vitro Susceptibility to Miltefosine of Leishmania Infantum (Syn. L. Chagasi) Isolates from Different Geographical Areas in Brazil
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
Food and Drug Law Journal
Top View
Manufacturing Generic Drugs
830716B897e6fdbcf465fbc59d4c
Two Cases of Relapsed HIV-Associated Visceral
IMPAVIDO (Miltefosine) Capsules, for Oral Use Fertility in Male Rats and Impaired Fertility in Female Rats
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Drug Formulary Update, July 2016 Commercial and State Programs
Review HIV-1 Protease Inhibitors for Treatment of Visceral Leishmaniasis
Rxoutlook® 3Rd Quarter 2020
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
Antileishmanial Activity of HIV Protease Inhibitors
Use of Miltefosine in a Patient with Mucosal Leishmaniasis and HIV-Coinfection: a Challenge in Long-Term Management
Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure
2021 Aetna Standard Plan
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Treatment of Leishmaniasis in HIV-Positive Patients
Uva-DARE (Digital Academic Repository)
CURRENT WORK PLAN New Monographs for Inclusion in The
Current Treatment of Leishmaniasis: a Review Lianet Monzote*
In Vitro Effectivity of Three Approved Drugs and Their Synergistic Interaction Against Leishmania Infantum
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
Leishmanicidal Therapy Targeted to Parasite Proteases
Interactions with Entry & Integrase Inhibitors
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Amphotericin B for Treatment of Visceral Leishmaniasis: Systematic Review and Meta-Analysis of Prospective Comparative Clinical Studies Including Dose-Ranging Studies
Miltefosine — Discovery of the Antileishmanial Activity of Phospholipid Derivatives
Miltefosine Represses HIV-1 Replication in Human Dendritic Cell/T-Cell Cocultures Partially by Inducing Secretion of Type-I Interferon
Liposomal Amphotericin B As a Treatment for Human Leishmaniasis 1
Leishmaniasis in the Americas. Treatment Recommendations
WHO Model List of Essential Medicines
Infected Patients in Ethiopia
Quantification of Total Polyphenols, Catechin, Caffeine, L-Theanine
Download (Accessed on 20 July 2019)
PDF) S1 Approval
Development of a Fluorescent Assay to Search New Drugs Using Stable Tdtomato-Leishmania, and the Selection of Galangin As a Candidate with Anti-Leishmanial Activity
1 Antiparasitic December 2016 Miltefosine (Impavido, Paladin Therapeutics) Non-Formulary
Kansas AIDS Drug Assistance Program Formulary
Drugs Formulary
(12) Patent Application Publication (10) Pub. No.: US 2007/0213382 A1 Rudy Et Al
(12) Patent Application Publication (10) Pub. No.: US 2003/0022909 A1 MOSS Et Al
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
The Initial Effectiveness of Liposomal Amphotericin B (Ambisome)
Rxoutlook® 1St Quarter 2021
Challenging New Targets for CNS–HIV Infection
In Vitro and in Vivo in Leishmania Braziliensis: Involvement of Reactive Oxygen Species As a Mechanism of Action
Visceral Leishmaniasis Relapse Hazard Is Linked to Reduced Miltefosine Exposure in Patients from Eastern Africa: a Population Pharmacokinetic/Pharmacodynamic Study
Application for Inclusion of Miltefosine on WHO Model List of Essential Medicines November 2010 Submission
September 2014 CPG Updates
Treatment Options for Visceral Leishmaniasis and HIV Coinfection
Addressing Pediatric Needs of the Most Neglected: Next Steps
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Box 1. Recommended Treatment Regimens for Visceral Leishmaniasis, Ranked by Preference1 Anthroponotic Visceral Leishmaniasis
Supplemental Tables
Miltefosine for Bolivian Cutaneous Leishmaniasis
In Vitro and in Vivo Interactions Between Miltefosine and Other Antileishmanial Drugs Karin Seifert and Simon L
Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit